Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Last Updated: June 9, 2023

Investigational Drug Information for Nepicastat

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

What is the development status for investigational drug Nepicastat?

Nepicastat is an investigational drug.

There have been 5 clinical trials for Nepicastat. The most recent clinical trial was a Phase 2 trial, which was initiated on April 1^st 2013.

The most common disease conditions in clinical trials are Cocaine-Related Disorders, Stress Disorders, Traumatic, and Stress Disorders, Post-Traumatic. The leading clinical trial sponsors are Biotie Therapies Inc., National Institute on Drug Abuse (NIDA), and Acorda Therapeutics.

Summary for Nepicastat

US Patents	0
International Patents	0
US Patent Applications	183
WIPO Patent Applications	73
Japanese Patent Applications	38
Clinical Trial Progress	Phase 2 (2013-04-01)
Vendors	46

Recent Clinical Trials for Nepicastat

Title	Sponsor	Phase
A Phase 1b Study to Evaluate APL-1401 in Patients With Moderately to Severely Active Ulcerative Colitis	Jiangsu Yahong Meditech Co., Ltd aka Asieris	Phase 1
A Multi-Center Trial of Nepicastat for Cocaine Dependence	National Institute on Drug Abuse (NIDA)	Phase 2
Nepicastat for Posttraumatic Stress Disorder (PTSD) in OIF/OEF Veterans	Acorda Therapeutics	Phase 2

See all Nepicastat clinical trials

Clinical Trial Summary for Nepicastat

Top disease conditions for Nepicastat

Top clinical trial sponsors for Nepicastat

See all Nepicastat clinical trials

US Patents for Nepicastat

+ Get email alerts for changes to this table

Subscribe to access the full database, or Try a Trial
Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
>Drugname	>Patent Number	>Patent Title	>Patent Assignee	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys

Johnson and Johnson

Boehringer Ingelheim

AstraZeneca

Harvard Business School

Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.